Search results
Results from the WOW.Com Content Network
Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...
The Sacklers and Purdue Pharma boosted their settlement contribution to $7.4 billion after the U.S. Supreme Court overturned a prior settlement in June 2024. If approved, the new plan would end ...
Purdue Pharma and the members of the Sackler family who own the company agreed in principle to pay a $7.4 billion settlement to resolve thousands of lawsuits over their alleged role in the opioid ...
Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024), is a United States Supreme Court case regarding Chapter 11 of the Bankruptcy Code. [1] The case addressed the 2022-2023 Purdue Pharma bankruptcy settlement and whether, under Chapter 11 of the Bankruptcy Code, a release extinguishing claims held by nondebtors against nondebtor third parties, without the claimants’ consent could move forward.
Under the new settlement, the Sacklers will pay $6.5 billion, with another $900 million coming from Purdue, without fully shutting off lawsuits from states, local governments, or individual ...
(The Center Square) – Colorado is set to get $81 million if a settlement between a coalition of states, the Sackler family and Purdue Pharma is approved. Colorado’s portion would be part of a ...
Proponents of Purdue Pharma’s settlement plan often assert that federal law does not prohibit third-party releases and that they can be necessary to create a settlement that parties will agree to.
For example, Purdue Pharmaceuticals entered an agreement with the United States, pleading guilty to felony misbranding of OxyContin with intent to defraud and mislead under sections 33 1(a) and 333(a)(2) of the FD&C Act and agreed to pay more than $600 million, but only $160 million was allocated to resolve civil claims under the False Claims ...